Research challenges for drug-induced birth defects.
Drug-induced birth defects (teratogenesis) represent unique adverse drug reactions (ADRs). Not only is the ADR manifest in a subject other than the one for whom treatment is intended, but most teratogens can be identified only after a drug is marketed. We know little about fetal safety for most marketed drugs, and identification of potential teratogens uniquely requires that study designs consider issues related to the effects of specific drugs, specific defects, and specific gestational timing.